GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Cyclically Adjusted Price-to-FCF

Gentian Diagnostics AS (OSL:GENT) Cyclically Adjusted Price-to-FCF : (As of Jun. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Gentian Diagnostics AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Cyclically Adjusted Price-to-FCF Chart

Gentian Diagnostics AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gentian Diagnostics AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Gentian Diagnostics AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Gentian Diagnostics AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Gentian Diagnostics AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.291/136.1000*136.1000
=0.291

Current CPI (Mar. 2025) = 136.1000.

Gentian Diagnostics AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 98.600 0.000
201509 0.000 100.600 0.000
201512 0.000 100.900 0.000
201603 -0.156 102.500 -0.207
201606 -0.343 103.800 -0.450
201609 -0.526 104.200 -0.687
201612 -0.322 104.400 -0.420
201703 -1.827 105.000 -2.368
201706 0.679 105.800 0.873
201709 -0.504 105.900 -0.648
201712 -0.173 106.100 -0.222
201803 -1.218 107.300 -1.545
201806 -0.520 108.500 -0.652
201809 -0.424 109.500 -0.527
201812 0.271 109.800 0.336
201903 -0.477 110.400 -0.588
201906 -0.777 110.600 -0.956
201909 -0.625 111.100 -0.766
201912 0.221 111.300 0.270
202003 -0.659 111.200 -0.807
202006 0.101 112.100 0.123
202009 -0.576 112.900 -0.694
202012 0.010 112.900 0.012
202103 -0.757 114.600 -0.899
202106 -0.445 115.300 -0.525
202109 -0.398 117.500 -0.461
202112 -1.018 118.900 -1.165
202203 -0.883 119.800 -1.003
202206 -0.478 122.600 -0.531
202209 0.188 125.600 0.204
202212 -0.700 125.900 -0.757
202303 -0.282 127.600 -0.301
202306 0.387 130.400 0.404
202309 -0.182 129.800 -0.191
202312 0.788 131.900 0.813
202403 -0.040 132.600 -0.041
202406 -0.207 133.800 -0.211
202409 0.847 133.700 0.862
202412 -0.466 134.800 -0.470
202503 0.291 136.100 0.291

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gentian Diagnostics AS  (OSL:GENT) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Gentian Diagnostics AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gentian Diagnostics AS Business Description

Traded in Other Exchanges
Address
Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Gentian Diagnostics AS Headlines